Dr Alex Staudacher

Research Interests

Cancer Diagnosis Cancer Therapy Radiation Therapy Radiology and Organ Imaging Cancer Biology and Clinical Oncology Innovative Therapeutics

Dr Alex Staudacher

Centre for Cancer Biology

College of Health

Eligible to supervise Masters only (as Co-Supervisor) - email supervisor to discuss availability.

Dr Alex StaudacherPostdoctoral Research Scientist, Translational Oncology Laboratory, SA Pathology.In a bench to bedside effort, researchers in the Translational Oncology Laboratory are applying advances in immunotherapeutic technologies to the treatment of melanoma, ovarian, brain and lung cancers, which affect millions around the world. The two major technologies of interest are antibody therapies using antibody drug conjugates and radioimmunotherapy to target and kill cancer cells, and chimeric antigen receptors (CARs) for re-directing lymphocytes toward cancers.We are developing pre-clinical and clinical approaches for the treatment of these cancers to aid in diagnosis, therapy monitoring and treatment. Much of our research is collaborative, working in association with the RAH Cancer Clinical Trials Unit and partnering with other laboratories within the Centre for Cancer Biology and SAHMRI as well as national and international collaborations.Projects in our Laboratory cover the development of novel non-invasive imaging techniques to monitor responses to anti-cancer therapy, using radiolabelled antibodies to target and irradiate tumours from the inside out, identifying novel targets and payloads for antibody drug conjugate therapy and using the bodies own immune system to kill cancer cells through immunotherapy and CAR T-cell therapy.

Date Position Institution name
2016 - ongoing Adjunct Research Associate University of South Australia
2014 - ongoing Affiliate Lecturer University of Adelaide

Date Institution name Country Title
2007 - 2011 Flinders University Australia PhD
2003 - 2006 Flinders University Australia Bachelor of Science (Hons)

Year Citation
2025 Liapis, V., Wittwer, N. L., Tieu, W., Gargett, T., Brown, M. P., & Staudacher, A. H. (2025). Detection of immune-mediated tumour cell death in vivo using Zirconium-89-labeled APOMAB®. Journal of Translational Medicine, 23(1, article no. 651), 651-1-651-18.
DOI Scopus1 WoS1 Europe PMC1
2023 Wittwer, N. L., Staudacher, A. H., Liapis, V., Cardarelli, P., Warren, H., & Brown, M. P. (2023). An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. Journal for ImmunoTherapy of Cancer, 11(3), e006274-1-e006274-16.
DOI Scopus23 WoS25 Europe PMC17
2023 Wittwer, N. L., Brown, M. P., Liapis, V., & Staudacher, A. H. (2023). Antibody drug conjugates: hitting the mark in pancreatic cancer?. Journal of Experimental and Clinical Cancer Research, 42(1, article no. 280), 280-1-280-16.
DOI Scopus24 WoS21 Europe PMC19
2022 Staudacher, A. H., Li, Y., Liapis, V., & Brown, M. P. (2022). The RNA-binding protein La/SSB associates with radiation-induced DNA double-strand breaks in lung cancer cell lines. Cancer Reports, 5(8), e1543-1-e1543-11.
DOI Scopus6 WoS6 Europe PMC4
2022 Nazarizadeh, A., Staudacher, A. H., Wittwer, N. L., Turnbull, T., Brown, M. P., & Kempson, I. (2022). Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives. International Journal of Molecular Sciences, 23(9), 4707-1-4707-15.
DOI Scopus36 WoS32 Europe PMC26
2022 Staudacher, A. H., Liapis, V., Wittwer, N. L., Tieu, W., Lam, H. C., Leusen, J., & Brown, M. P. (2022). Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®. Biomedicine and Pharmacotherapy, 151(article no. 113090), 113090-1-113090-10.
DOI WoS1
2022 Hull, A., Li, Y., Bartholomeusz, D., Hsieh, W., Tieu, W., Pukala, T. L., . . . Bezak, E. (2022). Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma.. Cells, 11(19), 1-18.
DOI Scopus5 WoS3 Europe PMC3
2021 MacGregor, M., Safizadeh Shirazi, H., Chan, K. M., Ostrikov, K., McNicholas, K., Jay, A., . . . Vasilev, K. (2021). Cancer cell detection device for the diagnosis of bladder cancer from urine. Biosensors and Bioelectronics, 171(112699), 12 pages.
DOI Scopus38 WoS32 Europe PMC24
2021 Liapis, V., Tieu, W., Wittwer, N. L., Gargett, T., Evdokiou, A., Takhar, P., . . . Staudacher, A. H. (2021). Positron emission tomographic imaging of tumor cell death using zirconium-89-labeled APOMAB® following cisplatin chemotherapy in lung and ovarian cancer xenograft models. Molecular Imaging and Biology, 23(6), 914-928.
DOI Scopus8 WoS9 Europe PMC6
2021 Reid, P., Staudacher, A. H., Marcu, L. G., Olver, I., Moghaddasi, L., Brown, M. P., & Bezak, E. (2021). Characteristic differences in radiation-induced DNA damage response in human papillomavirus-negative and human papillomavirus-positive head and neck cancers with accumulation of fractional radiation dose. Head and Neck, 43(10), 3086-3096.
DOI Scopus1 WoS1 Europe PMC1
2021 Liapis, V., Tieu, W., Wittwer, N. L., Gargett, T., Evdokiou, A., Takhar, P., . . . Staudacher, A. H. (2021). Correction to: Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models (Molecular Imaging and Biology, (2021), 23, 6, (914-928), 10.1007/s11307-021-01620-1). Molecular Imaging and Biology, 23(6), 929.
DOI
2020 Liapis, V., Tieu, W., Rudd, S. E., Donnelly, P. S., Wittwer, N. L., Brown, M. P., & Staudacher, A. H. (2020). Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®. EJNMMI Radiopharmacy and Chemistry, 5(1), 27-1-27-15.
DOI Scopus11 WoS13 Europe PMC10
2020 Reid, P., Staudacher, A. H., Marcu, L. G., Olver, I., Moghaddasi, L., Brown, M. P., & Bezak, E. (2020). Influence of the human papillomavirus on the radio-responsiveness of cancer stem cells in head and neck cancers. Scientific Reports, 10(1), 1-8.
DOI Scopus12 WoS13 Europe PMC10
2020 Reid, P., Staudacher, A. H., Marcu, L. G., Olver, I., Moghaddasi, L., Brown, M. P., . . . Bezak, E. (2020). Intrinsic Radiosensitivity Is Not the Determining Factor in Treatment Response Differences between HPV Negative and HPV Positive Head and Neck Cancers.. Cells, 9(8), 1-14.
DOI Scopus7 WoS7 Europe PMC6
2020 Staudacher, A. H., Liapis, V., Tieu, W., Wittwer, N., & Brown, M. P. (2020). Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody. Journal of Controlled Release, 327, 779-787.
DOI Scopus9 WoS10 Europe PMC8
2020 Liapis, V., Tieu, W., Wittwer, N., Gargett, T., Evdokiou, A., Takhar, P., . . . Staudacher, A. H. (2020). Positron Emission Tomographic imaging of tumor cell death using Zirconium-89-labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models.
DOI
2020 Liapis, V., Tieu, W., Wittwer, N., Gargett, T., Evdokiou, A., Takhar, P., . . . Staudacher, A. H. (2020). Positron Emission Tomographic imaging of tumor cell death using Zirconium-89-labeled APOMAB® following cisplatin chemotherapy in lung and ovarian cancer xenograft models.
DOI
2019 Staudacher, A. H., Li, Y., Liapis, V., Hou, J. J. C., Chin, D., Dolezal, O., . . . Brown, M. P. (2019). APOMAB antibody-drug conjugates targeting dead tumor cells are effective in vivo. Molecular Cancer Therapeutics, 18(2), 335-345.
DOI Scopus18 WoS18 Europe PMC16
2019 Reid, P., Marcu, L. G., Olver, I., Moghaddasi, L., Staudacher, A. H., & Bezak, E. (2019). Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in cancer stem cell heterogeneity, plasticity and treatment response. Radiotherapy and Oncology, 135, 1-12.
DOI Scopus33 WoS30 Europe PMC25
2018 Staudacher, A. H., Liapis, V., & Brown, M. P. (2018). Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates. Antibody Therapeutics, 1(2), 55-63.
DOI Scopus21
2018 Lopez, T., Ramirez, A., Benitez, C., Mustafa, Z., Pham, H., Sanchez, R., & Ge, X. (2018). Selectivity Conversion of Protease Inhibitory Antibodies.. Antibody therapeutics, 1(2), 55-63.
DOI Europe PMC2
2018 Reid, P., Wilson, P., Li, Y., Marcu, L., Staudacher, A., Brown, M., & Bezak, E. (2018). Experimental investigation of radiobiology in head and neck cancer cell lines as a function of HPV status, by MTT assay. Scientific Reports, 8(1), 7 pages.
DOI Scopus10 WoS9 Europe PMC5
2017 Reid, P., Wilson, P., Li, Y., Marcu, L. G., Staudacher, A. H., Brown, M. P., & Bezak, E. (2017). In vitro investigation of head and neck cancer stem cell proportions and their changes following X-ray irradiation as a function of HPV status. PLoS ONE, 12(10), 16 pages.
DOI Scopus20 WoS18 Europe PMC17
2017 Staudacher, A. H., & Brown, M. P. (2017). Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?. British Journal of Cancer, 117(12), 1736-1742.
DOI Scopus416 WoS382 Europe PMC341
2016 Ormsby, R., Staudacher, A., Blyth, B., Bezak, E., & Sykes, P. (2016). Temporal responses to X-radiation exposure in spleen in the pKZ1 mouse recombination assay. Radiation Research, 185(6), 623-629.
DOI Scopus4 WoS4 Europe PMC3
2016 Al Darwish, R., Staudacher, A. H., Li, Y., Brown, M. P., & Bezak, E. (2016). Development of a transmission alpha particle dosimetry technique using A549 cells and a Ra-223 source for targeted alpha therapy. Medical Physics, 43(11), 6145-6153.
DOI Scopus10 WoS10 Europe PMC9
2015 Al Darwish, R., Staudacher, A., Bezak, E., & Brown, M. (2015). Autoradiography imaging in targeted alpha therapy with Timepix detector. Computational and Mathematical Methods in Medicine, 2015(612580), 612580-1-612580-7.
DOI Scopus15 WoS9 Europe PMC9
2015 Pishas, K., Adwal, A., Neuhaus, S., Clayer, M., Farshid, G., Staudacher, A., & Callen, D. (2015). XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Scientific Reports, 5(1), 11465-1-11465-16.
DOI Scopus22 WoS21 Europe PMC18
2015 Pishas, K. I., Adwal, A., Neuhaus, S. J., Clayer, M. T., Farshid, G., Staudacher, A. H., & Callen, D. F. (2015). Erratum: XI-006 induces potent p53-independent apoptosis in Ewing sarcoma (Scientific Reports (2015) 5:11465) doi: 10.1038/srep11465). Scientific Reports, 5(1), 1 page.
DOI Scopus1 WoS1
2014 Penfold, S., Brown, M., Staudacher, A., & Bezak, E. (2014). Monte Carlo simulations of dose distributions with necrotic tumor targeted radioimmunotherapy. Applied Radiation and Isotopes, 90, 40-45.
DOI Scopus10 WoS8 Europe PMC7
2014 Staudacher, A., Bezak, E., Borysenko, A., & Brown, M. (2014). Targeted [alpha]-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation. Nuclear Medicine Communications, 35(12), 1284-1290.
DOI Scopus20 WoS20 Europe PMC21
2014 Brown, M., & Staudacher, A. (2014). Could bystander killing contribute significantly to the antitumor activity of brentuximab vedotin given with standard first-line chemotherapy for Hodgkin lymphoma?. Immunotherapy, 6(4), 371-375.
DOI Scopus14 WoS12 Europe PMC10
2014 Al-Ejeh, F., Staudacher, A., Smyth, D., Darby, J., Denoyer, D., Tsopelas, C., . . . Brown, M. (2014). Postchemotherapy and tumor-selective targeting with the la-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. Journal of Nuclear Medicine, 55(5), 772-779.
DOI Scopus16 WoS15 Europe PMC15
2014 Staudacher, A., Al-ejeh, F., Fraser, C., Darby, J., Roder, D., Ruszkiewicz, A., . . . Brown, M. (2014). The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the la-specific antibody APOMAB®. EJNMMI Research, 4(article no. 2), 2-1-2-13.
DOI Scopus24 WoS21 Europe PMC22
2014 AL Darwish, R., Bezak, E., Staudacher, A., & Brown, M. (2014). EP-1839: Application of timepix for autoradiography imaging in targeted alpha therapy. Radiotherapy and Oncology, 111, S302-S303.
DOI
2010 Staudacher, A., Blyth, B., Lawrence, M., Ormsby, R., Bezak, E., & Sykes, P. (2010). If bystander effects for apoptosis occur in spleen after low-dose irradiation in vivo then the magnitude of the effect falls within the range of normal homeostatic apoptosis. Radiation Research, 174(6), 727-731.
DOI Scopus13 WoS12 Europe PMC9
2010 Blyth, B. J., Azzam, E. I., Howell, R. W., Ormsby, R. J., Staudacher, A. H., & Sykes, P. J. (2010). An adoptive transfer method to detect low-dose radiation-induced bystander effects in vivo. Radiation Research, 173(2), 125-137.
DOI Scopus14 WoS15 Europe PMC11

Year Citation
2025 Elz, A., Staudacher, A., Liapis, V., Brown, M., Wheatcroft, M., & Ivashkevich, A. (2025). Girentuximab (TLX250) as a theranostic tool in triple-negative breast cancer treatment. In NUCLEAR MEDICINE AND BIOLOGY Vol. 150 (pp. 1 page). ELSEVIER SCIENCE INC.
DOI
2016 Pishas, K., Neuhaus, S., Clayer, M., Farshid, G., Staudacher, A., & Callen, D. (2016). XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. In CLINICAL CANCER RESEARCH Vol. 22 (pp. 2 pages). Salt Lake, UT: AMER ASSOC CANCER RESEARCH.
DOI WoS1
2014 Al Darwish, R., Bezak, E., Staudacher, A., & Brown, M. (2014). Application of timepix for autoradiography imaging in targeted alpha therapy. In RADIOTHERAPY AND ONCOLOGY Vol. 111 (pp. S302-S303). ELSEVIER IRELAND LTD.

Year Citation
2023 Staudacher, A. (2023). APOMAB AS A THERANOSTIC TOOL IN CANCER TREATMENT. Poster session presented at the meeting of INTERNAL MEDICINE JOURNAL. WILEY.
2022 Staudacher, A. H., Liapis, V., Wittwer, N. L., Wheatcroft, M. P., & Brown, M. P. (2022). Clinical translation of the dead cancer cell-targeting antibody chimeric DAB4 (chDAB4) as a theranostic tool for diagnosing cancer treatment responses. Poster session presented at the meeting of EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. Barcelona, SPAIN: SPRINGER.
2013 Staudacher, A. H., & Brown, M. P. (2013). Synergistic anti-cancer response to chemotherapy and <SUP>177</SUP>Lu-labelled APOMAB<SUP>®</SUP> radioimmunotherapy in a preclinical model of lung cancer. Poster session presented at the meeting of EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. Lyon, FRANCE: SPRINGER.

  • Investigating novel antibody drug conjugates for treating lung cancer, NHMRC - Project Grant, 01/01/2017 - 30/04/2021

Date Role Research Topic Program Degree Type Student Load Student Name
2014 - 2017 Co-Supervisor Investigation of Timepix Radiation Detector for Autoradiography and Microdosimetry in Targeted Alpha Therapy Doctor of Philosophy Doctorate Full Time Miss Ruqaya Omar G Al Darwish

Connect With Me

External Profiles

Other Links